MAPK10 and hepatocellular carcinoma: The significant reduction of stromal cell signatures in the low-MAPK10 group could be confirmed by separating the HCC patients into the MAPK10 high and MAPK10 low groups (as explained previously) and performing cumulative scoring (Wilcoxon test, P = 5.427 × 10−20; Figure 2B).